Medivir's fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO PressReach · Sep 16, 2024
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer PressReach · Sep 15, 2024
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 PressReach · Sep 15, 2024
Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024 PressReach · Sep 15, 2024
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024) PressReach · Sep 15, 2024
Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024 PressReach · Sep 15, 2024
Watercrest Buena Vista Senior Living Community Celebrates 92% Resident Occupancy PressReach · Sep 14, 2024
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer PressReach · Sep 14, 2024
Exosome Therapeutics Market to Grow by USD 234.7 Million from 2024-2028, Driven by Rising Chronic Disease Cases and AI's Impact on Market Trends- Technavio PressReach · Sep 14, 2024
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 PressReach · Sep 14, 2024
